Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[SM-108].

Y Uzuka, Y Saito

    Gan No Rinsho. Japan Journal of Cancer Clinics
    |May 1, 1985
    PubMed
    Summary

    Low-dose SM-108 (4-carbamoylimidazolium 5-olate) successfully induced remission in atypical leukemia. Higher doses are recommended for adult acute lymphoblastic leukemia (ALL), with minimal side effects observed.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Crystallization of murine major histocompatibility complex class I H-2Kb with single peptides.

    Journal of molecular biology·1992
    Same author

    Response of lipoprotein lipase to calorie intake in streptozotocin-induced diabetic rats.

    Scandinavian journal of clinical and laboratory investigation·1992
    Same author

    [An immunohistological study of normal parotid gland].

    Nihon Jibiinkoka Gakkai kaiho·1992
    Same author

    Inhibition of intimal thickening of the carotid artery of rabbits and of outgrowth of explants of aorta by probucol.

    Atherosclerosis·1992
    Same author

    [Improvement of respiratory function with weight reduction in obese elderly].

    Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·1992
    Same author

    Stable expression of natriuretic peptide receptors: effects of HS-142-1, a non-peptide ANP antagonist.

    Biochemical and biophysical research communications·1992

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • SM-108 (4-carbamoylimidazolium 5-olate) is an agent investigated for its therapeutic potential in leukemia.
    • Understanding its efficacy and safety profile is crucial for clinical application.

    Purpose of the Study:

    • To evaluate the clinical usefulness of SM-108.
    • To determine the optimal administration method for SM-108.
    • To assess the side effects associated with SM-108 treatment.

    Main Methods:

    • Analysis of available clinical data on SM-108.
    • In vitro culture of leukemic cells (freshly isolated and cell lines) with SM-108.
    • Assessment of differentiation induction in leukemic cells.

    Main Results:

    • Successful remission induction in atypical leukemia was achieved with low-dose SM-108.
    • Minimal evidence of differentiation induction was observed in cultured cells.
    • Higher doses of SM-108, alone or in combination, were suggested for adult acute lymphoblastic leukemia (ALL).
    • Observed side effects, including myelotoxicity and gastrointestinal toxicity, were minimal.

    Conclusions:

    • SM-108 demonstrates potential in inducing remission for atypical leukemia.
    • The drug appears to have a favorable safety profile with minimal toxicity.
    • Further investigation into higher doses and combination therapies for adult ALL is warranted.

    Related Experiment Videos